For patients with advanced or metastatic pancreatic cancer, gemcitabine is the standard therapy; however, although gemcitabine therapy increases overall survival, response rates are low.

Eraglusib combined with gemcitabine and nab-paclitaxel significantly improved overall survival in metastatic pancreatic ductal adenocarcinoma patients. The combination therapy showed a favorable ...

BCG might be superior to sequential intravesical gemcitabine-docetaxel for reducing the risk of recurrence in patients with high-grade intermediate-risk NMIBC. Given the recent global shortage of ...

Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- The "Gemcitabine Hydrochloride Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...